In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Octreotide | Synthetic analog GHRP-6 | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Growth hormone axis | Growth hormone axis | |
| Evidence | |||
| Amount of evidence | 816 | 942 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 118 (116 in people) | 32 (11 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 256 · 30 active63 more mention it but do not test it | None registered | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Sandostatin says: “Reduction of GH and IGF-1 in acromegaly after inadequate response to, or inability to receive, surgery, pituitary irradiation, and maximally tolerated bromocriptine”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Octreotide | GHRP-6 |
|---|---|---|
| Growth hormone and IGF-1Kidney and urinary | 14513411 | 377117156 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 9 Oct 2026).
| Gastrointestinal protectionGastrointestinal | 91901 | 55 |
|---|
| Adverse eventsWhole body | 69672 | 20614 |
|---|
| Receptor activity and mechanismPharmacology | 35269 | 190167122 |
|---|
| Glycemic controlMetabolic and weight | 4747 | 183132 |
|---|
| Tumor growthEndocrine and hormones | 654916 | 22 |
|---|
| MortalityWhole body | 4040 | 44 |
|---|
| PharmacokineticsPharmacology | 21192 | 221372 |
|---|
| Blood pressureLiver | 22202 | 22 |
|---|
| Kidney functionKidney and urinary | 25169 | 33 |
|---|
| Body weightMetabolic and weight | 16142 | 1616 |
|---|
| Heart functionCardiovascular | 1192 | 2222 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
GHRP-6 differs from Ghrelin (human), ghrelin-28 at 5 positions.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Octreotide | GHRP-6 |
|---|---|---|
| Growth hormone and IGF-1Endocrine and hormonesCompared as: value in the arm that got the peptide, in % | 19.2% Biochemical control rate Dose studied: 20 mg/28 days, with optional titration to 30 mg at months 3 and 712 monthsn = 3582014 | No comparable result 15 randomized-trial results measure it in another way or another unit. |
| Gastrointestinal protectionGastrointestinalCompared as: difference from placebo, in p | 0.046 P P value Dose studied: 0.3 mg infusion followed by 0.1 mg at 6 and 12 h after infusionIntravenous infusion from 1 h before endoscopy to 6 h after; subcutaneous doses at 6 and 12 h after the infusion stoppedn = 8322007 | |
| MortalityWhole bodyCompared as: difference from placebo, in p | 0.34 P P value Dose studied: 30 mg once every 4 weeksup to 2 yearsn = 2722009 | No randomized trial result 4 results from other study designs. |
| Wound healingSkin and woundCompared as: value in the arm that got the peptide, in cc/day | 65.4 cc/day Mean daily lymphorrhea · octreotide group; reported +/- 21.1 Control group; reported +/- 19: 94.6 cc/day Dose studied: 0.1 mg three times a day5 daysn = 2612003 | |
| Tumor growthEndocrine and hormonesCompared as: difference from placebo, in p | 0.000072 P P value Dose studied: 30 mg monthlyn = 852009 | No randomized trial result |
| Liver fat and liver functionLiverCompared as: value in the arm that got the peptide, in ml | −130.2 mL TLV decrease · Shown as a change. The study reports a tlv decrease of this size. Dose studied: 40 mg monthly3 yearsn = 272016 | |
| Body weightMetabolic and weightCompared as: value in the arm that got the peptide, in kg | 1.6 kg Weight change, mean · octreotide group; SEM 0.6 Placebo group; SEM 1.7: 9.1 kg Dose studied: 5-15 microg/kg per day6 monthsn = 182003 | No randomized trial result 16 results from other study designs. |
| PharmacokineticsPharmacologyCompared as: value in the arm that got the peptide, in l/h | 15.8 L/h Apparent clearance · octreotide 100 microg Dose studied: 100 microgsingle dosen = 122005 | No randomized trial result 22 results from other study designs. |
| Kidney functionKidney and urinaryCompared as: value in the arm that got the peptide, in ml/1.73 m2 | 379 mL/1.73 m2 Mean total kidney volume · octreotide group, after 12 weeks Placebo group, after 12 weeks: 389 mL/1.73 m2 Dose studied: 300 micrograms/24 h12 weeksn = 111991 | |
| Glycemic controlMetabolic and weightCompared as: difference from placebo, in mg/dl h | 39 to 40 mg/dl h Difference in mean change of blood glucose AUC(0-180 min) vs placebo, OGTT 6 monthsn not reported2006 | No randomized trial result 18 results from other study designs. |
| Adverse eventsGastrointestinalCompared as: difference from placebo, in p | < 0.005 p p-value Dose studied: 3 x 100 micrograms7 days perioperativelyn = 2461992 | No randomized trial result 20 results from other study designs. |
19.2%
Biochemical control rate
Dose studied: 20 mg/28 days, with optional titration to 30 mg at months 3 and 712 monthsn = 3582014
No comparable result
15 randomized-trial results measure it in another way or another unit.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 256 trials, ranked by phase, then posted results and enrollment: 1 ongoing · 2 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Korea University1,034 participantsSept 2006 to May 2010
Variceal Bleeding, Cirrhosis
Novartis Pharmaceuticals429 participantsDec 2006 to Jun 2013
Carcinoid Tumor · Malignant Carcinoid Syndrome
National Cancer Institute (NCI)427 participants1 Dec 2007 to est. 31 Jan 2027
Colorectal Neuroendocrine Tumor G1 · Gastric Neuroendocrine Tumor G1 · Neuroendocrine Neoplasm · Neuroendocrine Tumor · Neuroendocrine Tumor G2
No randomized trial result 5 results from other study designs. |
No randomized trial result 10 results from other study designs. |
2 results from other study designs.
No randomized trial result 1 result from other study designs. |
No randomized trial result
3 results from other study designs.
0.046 P
P value
Dose studied: 0.3 mg infusion followed by 0.1 mg at 6 and 12 h after infusionIntravenous infusion from 1 h before endoscopy to 6 h after; subcutaneous doses at 6 and 12 h after the infusion stoppedn = 8322007
No randomized trial result
5 results from other study designs.
0.34 P
P value
Dose studied: 30 mg once every 4 weeksup to 2 yearsn = 2722009
No randomized trial result
4 results from other study designs.
65.4 cc/day
Mean daily lymphorrhea · octreotide group; reported +/- 21.1
Control group; reported +/- 19: 94.6 cc/day
Dose studied: 0.1 mg three times a day5 daysn = 2612003
No randomized trial result
10 results from other study designs.
0.000072 P
P value
Dose studied: 30 mg monthlyn = 852009
No randomized trial result
2 results from other study designs.
−130.2 mL
TLV decrease · Shown as a change. The study reports a tlv decrease of this size.
Dose studied: 40 mg monthly3 yearsn = 272016
No randomized trial result
1 result from other study designs.
1.6 kg
Weight change, mean · octreotide group; SEM 0.6
Placebo group; SEM 1.7: 9.1 kg
Dose studied: 5-15 microg/kg per day6 monthsn = 182003
No randomized trial result
16 results from other study designs.
15.8 L/h
Apparent clearance · octreotide 100 microg
Dose studied: 100 microgsingle dosen = 122005
No randomized trial result
22 results from other study designs.
379 mL/1.73 m2
Mean total kidney volume · octreotide group, after 12 weeks
Placebo group, after 12 weeks: 389 mL/1.73 m2
Dose studied: 300 micrograms/24 h12 weeksn = 111991
No randomized trial result
3 results from other study designs.
39 to 40 mg/dl h
Difference in mean change of blood glucose AUC(0-180 min) vs placebo, OGTT
6 monthsn not reported2006
No randomized trial result
18 results from other study designs.
< 0.005 p
p-value
Dose studied: 3 x 100 micrograms7 days perioperativelyn = 2461992
No randomized trial result
20 results from other study designs.
63 more mention it but do not test it. They only measure it or name it in their text.
No registered trial that tests GHRP-6 found in ClinicalTrials.gov.